BRG1/SMARCA4
GR390/Rabbit/Monoclonal
Gene Bio Solution BRG1/SMARCA4 Antibody. Gene bio solution’s rabbit recombinant monoclonal antibody recognizes BRG1/SMARC4, a protein that is mutated in multiple human tumors, including the hypercalcemic type of small cell carcinoma of the ovary and uterine sarcoma and undifferentiated carcinoma.
BRG1/SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) encodes a protein involved in chromatin remodeling, which is important for regulating the binding of transcription factors to DNA. BRG1/SMARCA4 is an evolutionarily conserved regulator of many transcription factors where loss of BRG1/SMARCA4 characterizes several distinct neoplasms, including small cell carcinoma of the ovary hypercalcemic type, SMARCA4 deficient undifferentiated uterine sarcoma and SMARCA4 deficient thoracic tumors.
BRG1/SMARCA4 can be useful to aid in the diagnosis of ovarian small cell carcinoma, hypercalcemic type (ovarian rhabdoid tumor), SMARCA4 deficient thoracic tumors, SMARCA4 deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus), SMARCA4 deficient undifferentiated malignant neoplasms arising at other anatomic locations, including the gastrointestinal tract and skin, and poorly differentiated chordoma.
BRG-1/SMARCA4 (also designated SNF2β) and BRM are the ATPase subunits of the mammalian SWI/SNF complex. The SWI-SNF complex is involved in the activation of transcription via the remodeling of nucleosome structure in an ATP-dependent manner. BRG1/SMARCA4 is mutated in multiple human tumors, including the hypercalcemic type of small cell carcinoma of the ovary and uterine sarcoma and undifferentiated carcinoma.
